Prognostic Value of Nivolumab Clearance in Non-Small Cell Lung Cancer Patients for Survival Early in Treatment.

Leila-Sophie OttenBerber PietDemy van den HaakRobert D SchoutenMilou SchuurbiersSushil K BadrisingEmmy BoerrigterSjaak A BurgersRob Ter HeineMichel M van den Heuvel

Published in: Clinical pharmacokinetics (2023)

Nivolumab clearance is indicative of survival early in treatment. Our results encourage to further assess the prognostic potential of immunotherapy clearance.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
combination therapy
patient reported outcomes
human health